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The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We
review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and
neurodegeneration in AD. We elaborate on and update arguments for and against the amyloid hypothesis with
new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically. We note
several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the
weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and
role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the
poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how
extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted
independently of a role for Aβ in AD. We conclude it is essential to expand our view of pathogenesis beyond Aβ
and tau pathology and suggest several future directions for AD research, which we argue will be critical to
understanding AD pathogenesis.
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“Whenever a theory appears to you as the only
possible one, take this as a sign that you have neither
understood the theory nor the problem which it was
intended to solve.”– Karl Popper
A hypothesis that remains unproven yet catches the
collective imagination can become, with the passage of
time, so seductive that it dominates peer review opinion
and arrests the development of alternative ideas. Such is
the case for the amyloid hypothesis of AD. From the
mid-1980s [1,2] this hypothesis began to give focus and
excitement to what had been an unstructured research* Correspondence: brycevissel@gmail.com
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unless otherwise stated.field with dozens of complex and unrelated theories [3],
none of which dominated. It became a simple and effect-
ive way to describe AD pathogenesis to funding bodies,
pharmacological companies, and the public at large.
The hypothesis arose through the input of researchers
with a history of observing prion particles [4,5] seeing par-
allels between these entities in brain sections in Creutzfeld-
Jacob disease and the plaques in AD brain, described years
earlier [6]. It warrants recalling that a commentary [7]
notes Alzheimer devoting only two sentences of his 1907
text to these plaques, and there being no reason to sup-
pose that he or indeed anyone until the early 1980s, saw
them as causal.
When Prusiner and Master's interest in these plaques
began, others showed they consisted of a novel amyloid
fibril [1,8] containing highly aggregating small polypep-
tides about 40 amino acids long with a molecular mass of
4kDa, now known as amyloid-beta (Aβ) [9]. The dense
fibre-like tangles Alzheimer noted, now termed neurofi-
brilliary tangles (NFTs), contain bundles of paired helical
filaments of the microtubule associated protein tau [10].
The 1980s ended with a report that the Aβ peptide derivedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11], transforming a histological parallel into the amyloid
theory of disease pathogenesis.
Hence the basis of AD became, in essence, Aβ killing
neurons, and later also Aβ killing synapses, despite the
syndrome clearly being more subtle and complex and
the fact that histopathology lesions have a poor record
of being causal in disease pathogenesis. Although the
amyloid hypothesis has shifted its focus from plaque to
soluble forms of Aβ, it largely remains defined by the
central tenet that accumulation of amyloid, in a variety
of forms, triggers a cascade that harms neurons and
synapses (Figure 1).Figure 1 The Amyloid Hypothesis. The amyloid hypothesis
postulates that Aβ aggregation triggers a cascade of events
ultimately resulting in AD. Familial mutations in PSEN1, PSEN2 or
APP are associated with early-onset AD (EOAD). These genetic risk
factors are postulated to impact the cleavage of Aβ from APP,
leading to oligomerisation and eventual Aβ plaque formation.
Individuals with trisomy 21 (Down’s Syndrome), and therefore a
triple copy of APP, suffer EOAD. The strongest genetic risk factor for
late-onset AD (LOAD) is the presence of at least one APOE4 allele. It
is unclear as to what triggers Aβ accumulation in LOAD, though it
is suggested that there may be a number of contributing factors
such as reduced Aβ clearance due to APOE genotype. Aβ
oligomerisation is proposed to trigger a cascade involving the
formation of neurofibrilliary tangles (NFTs) composed of
hyperphosphorylated tau, synapse loss, neuron death and
widespread neuroinflammation, particularly in brain regions
involved in learning and memory, such as the hippocampus. As the
amyloid burden increases, the ongoing catastrophic loss of
synapses and neurons is thought to lead to progressive dementia.The amyloid hypothesis has become difficult to chal-
lenge because it is so often the lens through which peer
reviewers, granting bodies and pharmaceutical com-
panies view, judge and support AD research. Thus
new non-amyloid data tends to be couched in terms
that place it within the amyloid hypothesis and many
authors tacitly ignore valid, but quite different,
interpretations.
We show here however that the central conclusion of
the amyloid hypothesis, that Aβ is the cause of AD is,
at very least, premature. Aβ is one product of amyloid
precursor protein (APP) processing. Current data does
support a conclusion that aberrant expression and pro-
cessing of APP may sometimes cause human familial
AD (FAD), also called early-onset AD (EOAD), and
that Aβ, in excess, can be toxic. However, data does
not support a conclusion that aberrant Aβ expression
is the cause of sporadic AD, also known as late-onset
AD (LOAD). In fact as we show data suggests that ab-
errant Aβ expression may not be the primary cause of
all EOAD. Instead, it may more often play a role, per-
haps secondary, as part of more complex processes in
the CNS. We suggest the field has matured sufficiently,
with a range of alternative interpretations available,
that a strong prospect for a change in direction exists
that could provide a major advance in disease under-
standing and clinical interventions.
The Amyloid Hypothesis
The amyloid hypothesis postulates that amyloid-beta
(Aβ), in a variety of forms, triggers a cascade harming
synapses and ultimately neurons, producing the patho-
logical presentations of Aβ plaques, tau tangles, synapse
loss and neurodegeneration, leading to dementia. Aβ
accumulation is thought to initiate AD pathology by
destroying synapses, causing formation of NFTs, and
subsequently inducing neuron loss (Figure 1). Although
some changes to the hypothesis have occurred since
the original publications, notably a shift toward defining
soluble Aβ oligomers as the toxic agent, rather than
plaques, the theory and the way data is interpreted have
remained largely the same, i.e. Aβ accumulation as olig-
omers or plaques triggers AD. A large, growing litera-
ture espouses the amyloid hypothesis. In this section we
summarise these data and how the dominance of this
hypothesis arose.
Putative evidence in support of the hypothesis
Using the amino acid sequence corresponding to Aβ [9],
the major constituent of amyloid plaques in AD, a precur-
sor gene cDNA to Aβ (the amyloid precursor protein, APP)
was sequenced and mapped to chromosome 21 [12]. This
finding had compelling implications in view of the observa-
tion many individuals with trisomy 21 (Down’s Syndrome)
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Such Down’s individuals would have a triple copy of APP,
and therefore it was reasoned, excess Aβ production. Since
Aβ is the main component of plaques seen in AD, it is pre-
sumed in turn that excess Aβ is the cause of AD in Down’s
syndrome. Surprisingly, the fact that not all people with
Down’s syndrome develop AD, despite plaques and in-
creased Aβ expression, did not receive significant attention
[13]. This observation may have quelled consideration of
Aβ as the sole risk factor for AD.
Next, studies of familial EOAD uncovered genetic
links between the APP gene and AD [14]. APP is proc-
essed into smaller peptide fragments, one of which isFigure 2 Cleavage of APP and Physiological roles of APP and APP Fra
mutually exclusive pathways. Importantly, various studies have suggested t
a number of possible roles in normal brain physiology, shown in the boxes. In
(beta-site APP cleaving enzyme 1 (BACE1)) and γ-secretase enzymes (PSEN1 is
β-secretase cleavage produces a large soluble extracellular domain, secreted a
C99 stud is then cleaved by multiple sequential γ-secretase cleavages. These b
(the ε-site) to produce the APP intracellular domain (AICD), and then subsequ
bound component to produce different length Aβ peptides including Aβ43,
APP is processed consecutively by α- and γ-secretases to produce secreted am
AICD. The major α-secretase enzyme is A Disintegrin and metalloproteinase d
non-amyloidogenic pathways depends on the cellular localisation of cleavage
in specific sub-cellular locations.Aβ, via cleavage by α-, β- and γ-secretases (Figure 2).
Importantly, EOAD-linked point mutations were identi-
fied not only in APP itself but also in presenilin-1 (PSEN1)
and presenilin-2 (PSEN2) [15,16] the key catalytic subunits
of γ-secretase, known to cleave APP (Figure 2). No known
AD-causing mutations are present in the gene encoding
the β-secretase gene, beta-site APP cleaving enzyme 1
(BACE1).
The genetic mutations are reasoned to cause AD through
aberrant processing of APP, leading to either increased
levels of Aβ or an increased production of the 42 and
43 amino acid forms of Aβ (Aβ42/Aβ43) over the 40
amino acid form of Aβ (Aβ40). It is argued this triggersgments. Amyloid precursor protein (APP) can be cleaved via two
hat these various fragments of APP processing, including Aβ, can have
the so-called amyloidogenic pathway APP is cleaved by β-secretase
the catalytic core of the multiprotein γ-secretase complex). The initial
myloid precursor protein-β (sAPPβ). The remaining membrane bound
egin near the inner membrane at a γ-secretase cleavage site epsilion
ent sequential γ-secretase cleavages trim the remaining membrane
Aβ42, Aβ40 and Aβ38 [17]. In the so-called non-amyloidogenic pathway
yloid precursor protein α (sAPPα), p3 (which is in effect Aβ17-40/42) and
omain-containing protein 10 (ADAM10). Cleavage via amyloidogenic and
enzymes, and of full-length APP, which are expressed and trafficked
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mice expressing familial human APP and PSEN muta-
tions recapitulate many, but not all, of the features of
the human disease [18] further established the link
between aberrant Aβ production and the AD pheno-
type. This latter discovery, perhaps more than any
other, tied the field to the amyloid hypothesis for the
next decades.
The conclusions of the aforementioned studies were
grounded in an unquestioned assumption that Aβ, rather
than altered expression of APP or its products, causes AD
pathology. The assumption arose because Aβ was the key
component of plaques and because Aβ caused neurotox-
icity in healthy cells [19]. Further, hyperphosphorylation of
tau, thought to be downstream of Aβ, was seen as a crit-
ical mediator of the neurotoxic effects of Aβ [20] placing
Aβ at the top of the pathological chain of AD events. A
cycle thus began to develop early whereby studies were
designed and then interpreted on the basis of the hy-
pothesis that Aβ caused AD pathology, rather than be-
ing critically evaluated in the context of a range of
possible interpretations.
Further, given the impact discoveries of mutations in
APP, PSEN1 and PSEN2 have had in driving the amyloid
theory, it is notable that, while these mutations account
for the majority of EOAD cases, EOAD only comprises
less than 5% of all AD cases [21]. In fact, the majority of
AD cases are sporadic, idiopathic LOAD. It seems in
retrospect presumptive to have extrapolated a role for
Aβ in all AD based on the genetic evidence suggesting a
role for altered APP processing in EOAD.
In general, the risk genes identified for LOAD are subtle,
with no direct genetic association to the APP gene or its
processing enzymes. The most well-known genetic link
to LOAD is the apolipoprotein genotype E4 (APOE4)
[22]. Recently another strong risk gene for LOAD was
identified, a variant of the triggering receptor expressed
on myeloid cells 2 gene (TREM2), implicating excessive
innate immunity in Alzheimer’s pathogenesis [23]. Al-
though these two mutations have been the strongest
to date, many more have been associated with LOAD.
Most of these genetic risk factors have been interpreted
through the lens of the amyloid hypothesis, mainly by
considering their modulatory effects on Aβ, though
other interpretations are equally valid, an issue we dis-
cuss further in later sections.
The crucial role of synapse loss in AD
Synapse loss leads to a loss of dendritic mass [24] and,
crucially, may precede, and indeed drive, neuron loss in
a range of conditions [25]. Deficits in synaptic plasticity
are measurable at just one month of age in mouse
models of AD [26] and synapse loss is evident during
early stages of the human disease [27]. Elegant researchhas revealed the number of neocortical synapses to be a
better correlate of cognition than both Aβ plaques and
NFTs [28] and a greater loss of synapses than neurons is
evident in human AD brains [29]. These observations
place synapses at the forefront of understanding AD
pathogenesis. It has therefore been suggested that AD is
primarily a synaptic disorder [30,31]. In a mouse model
of AD, synapse loss arises from over-elimination of
synapses, rather than a failure of synapse formation [32].Putative evidence that Aβ causes synapse dysfunction and
loss in vitro and ex vivo
The obvious caveat of in vitro studies is that they may
not represent actual processes in the brain. Nevertheless,
much work focuses on the impact of Aβ oligomers on
synapses, most of it in in vitro or ex vivo culture
systems.
Key in vitro findings are summarised as follows; Aβ
oligomers bind exclusively and rapidly to synaptic termi-
nals [33], altering both pre- and postsynaptic structures
in cultured neurons and affecting excitatory, but not in-
hibitory nerve terminals [34]. The effects of Aβ on syn-
apse formation, neurite outgrowth and arborisation is
concentration-dependent [35] and rapidly decreases ex-
pression of memory related receptors such as NMDA
and EphB2 [33].
In ex vivo organotypic slices; physiological concentra-
tions of Aβ dimers and trimers, but arguably not mono-
mers, induce loss of hippocampal synapses, which
requires the activation of NMDARs [36]. Sub-lethal levels
of Aβ decrease spine density, increase spine length and
subdue spine motility [37]. Selective expression of APP in
pre- or postsynaptic neurons, resulting in either dendritic
or axonal Aβ overproduction, reduces spine density and
plasticity at nearby dendrites [38]. Some molecular mech-
anisms of Aβ-induced synaptic dysfunction and spine
shrinkage in these in vitro and ex vivo paradigms have
been suggested [39].Putative evidence that Aβ can lead directly to synapse
dysfunction in vivo
Despite several technical limitations, arguably the most dir-
ect evidence supporting the role of Aβ in synapse destruc-
tion in AD is that Aβ oligomers extracted from human AD
brain inhibit long-term potentiation (LTP), enhance long-
term depression (LTD), reduce dendritic spine density
and disrupt memory and learning in vivo when directly
injected into a mouse hippocampus [40]. Hippocampal
injections of soluble Aβ42 oligomers in vivo, in awake
mice, stimulate AD pathology including neuronal loss,
although this requires a regimen involving multiple in-
jections of highly concentrated Aβ [41]. Finally, trans-
genic mouse lines producing high levels of soluble Aβ
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density [42].
Is Aβ the central cause of synapse destruction in AD?
The aforementioned studies of Aβ at synapses are difficult
to interpret. Aβ plaque deposition can occur without
associated synapse loss [43], and conversely synapse and
dendritic tree loss can occur in areas without Aβ depos-
ition, although synapse loss does usually appear exacer-
bated near Aβ plaques [44]. Thus it would be prudent to
treat the suggestion that Aβ plaques have a primary
causative role in synapse destruction in human LOAD
with caution.
As for Aβ oligomers however, while many reports
identifying Aβ oligomers as triggers of synaptic degener-
ation support the amyloid hypothesis, technical restric-
tions limit interpretations of these results, and their
relevance to the human disease is unclear, as we discuss
below. For example, are pathological effects in mice
resulting from injection or over-expression of Aβ rele-
vant to the human condition?
Furthermore, synaptic gene dysregulation in early
AD can occur independently of alterations in the ex-
pression of APP and regulators of APP metabolism
[45]. Finally, genetic studies suggesting a role for APP
and its processing in familial EOAD may have been in-
correctly extrapolated to LOAD. Thus, as with plaques,
it is conceivable that Aβ oligomers play a role, but it
would also be prudent to treat the suggestion Aβ oligo-
mers play a primary or sole causative role in synapse
destruction with a degree of caution.
Later we discuss our view that understanding AD
requires first understanding the complex biology of
the multicellular synapses [46], the role of glia in
synapse removal, and the means by which these cells
can be driven towards excess synapse removal and/
or destruction.
The Amyloid Hypothesis and Recent Drug
Developments
Since the literature on AD has been largely Aβ-centric,
myriad studies provide much reassurance that the amyloid
hypothesis is on solid ground. As a result, the hypothesis
has maintained supremacy in driving drug development
efforts.
Much faith has been placed in AD mouse models,
built on and embedded in the amyloid hypothesis, as
the testing ground for new therapies. Beginning with a
1999 study by Schenk and colleagues [47], many studies
show that amyloid removal relieves AD symptoms in
mouse models of the disease. Since these mice produce
human amyloid, both active and passive immunization
strategies aimed at removing the putative causal Aβ, not
surprisingly, reduce fibrillar amyloid and Aβ plaquedeposition, result in fewer neuritic lesions, and protect
mice from cognitive decline [48]. Furthermore, inhibi-
tors of the enzymes that cleave Aβ from its membrane
bound precursor have been therapeutically investigated
both in mice and human studies (Table 1). Such posi-
tive outcomes rapidly led to Phase 1, 2 and 3 human
trials.The amyloid hypothesis has so far failed clinically
The Food and Drug Administration (FDA) has over the
years approved five drugs for AD; Donepzil, Galantamine,
Memantine, Rivastigimine and Tacrine. It is notable that
each of these are unrelated to the amyloid hypothesis and
were not tested in transgenic AD mice before being used
in the clinic [66].
Meanwhile, many anti-amyloid treatments that were
tested in mice have completed, or are undergoing, exten-
sive clinical trials in humans. We summarise the most
high profile of these drugs in Table 1. They are divided
into those directly targeting Aβ by active and passive
immunization, those targeting inhibition or modulation
of the γ-secretase APP cleaving enzyme (Figure 2), pre-
senilin, and those targeting the APP β-secretase cleavage
enzyme BACE1.
So far, anti-Aβ treatments have broadly failed to
meet their primary clinical endpoints and some major
phase 3 trials were halted early. None of the tested
treatments have produced a discernible functional re-
covery, or altered the course of disease. In fact alarm-
ingly some, specifically inhibitors of γ-secretase, lead
to an increased decline in cognition (Table 1). With
each successive failure the validity and foundations of
the amyloid hypothesis, on which these drugs have
been based, is called increasingly into question. Haste
to run Phase 3 trials without Phase 2 success, and similar
criticisms, have recently been made of this commercially-
driven enterprise [67].
Why is the hypothesis failing clinically? Some suggest
the disease is not being targeted early enough [68], not-
ing that in animal models anti-Aβ approaches clear
hyperphosphorylated tau aggregates when given to young,
but not old, animals [69] and, also, detailed analysis of re-
cent trials have shown hints of treatment benefit in indi-
viduals treated early in disease [57].
Planned human intervention studies aim to address
this issue in two ways. The DIAN [70] and the API
Colombia study [71] use anti-Aβ antibody treatments
in presymptomatic individuals at risk for familial
EOAD. If these trials succeed, the results will provide
evidence for a degree of Aβ involvement in EOAD.
They will not necessarily prove Aβ causality in all
EOAD, nor will they provide information on the role of
Aβ in LOAD.
Table 1 High profile clinical trials based on the amyloid hypothesis
Mechanism of
action
Drug name Clinical
phase
Key results from each trial Current status
(August 2014)
Reference
Active
immunisation
with Aβ
AN1792 2 Plaque Cleared. NFT reduced in neuronal processes, but not
cell bodies. Very few antibody responders (25/239). Reports of
encephalitis.
Discontinued [49,50]
CAD106 2 Favourable safety profile. Prolonged antibody titre in responders. Ongoing [51]
ACC001 2 Co-administration of adjuvant required for strong antibody response.
Generally safe and well-tolerated, no adverse related event.
Discontinued [52]
AD02 2 Favourable safety and tolerability profile. Did not reach primary or
secondary outcome measures in phase 2.
Ongoing [53]
Passive
immunization
against Aβ
Solanezumab 3 Worsening cognition compared to placebo, multiple adverse events. Terminated [54]
Bapinezmab 3 Engaged target. Reduction in cerebrospinal fluid phospho-tau in APOE4
carriers. Decreased rate of amyloid accumulation in APOE4 carriers. No
improvement in clinical outcomes in carrier or non-carriers of APOE4.
Negative amyloid scans in 36% of non-carriers.
Discontinued [55]
Gantenerumab 2/3 Safe and well-tolerated at phase 1. Focal inflammation in areas with
amyloid reduction a concern. Amyloid reductions compared to
placebo.
Recruiting for
Phase 3 DIAN
trial
[56]
Crenezumab 2 Did not meet co-primary endpoints. Trend of improved cognition in
people with mild disease.
Ongoing [57]
Ponezumab 2 Safe and well-tolerated at phase 1. Plasma Aβ40 increased at phase 2.
No effect on primary endpoints in phase 2.
Recruiting for
further Phase 2
trials
[58]
γ-Secretase
inhibitors
Avagacestat 2 Gastrointestinal and dermatological side effects at Phase 1. Also
dose-dependent pharmacodynamic effects on CSF biomarkers in
some patients. Trend towards worsening cognition at higher doses
compared to placebo. Amyloid related imaging abnormalities.
Discontinued [59]
Semagacestat 3 Dose-dependent reduction in Aβ synthesis at Phase 1. Reduced plasma
Aβ at Phase 2, but no differences in cognition. No improvement in
cognition and worsening cognition at higher doses compared to controls at
Phase 3.
Discontinued [60]
γ-Secretase
modulators
CHF5074 2 Anti-inflammatory at Phase 2. Trend towards improved function in APOE4
carriers.
Ongoing [61]
EVP-0962 2 Does not inhibit cleavage of γ-secretase substrates other than APP. Ongoing [62]
Tarenflurbil 3 Small functional benefit at higher doses in mild AD but no cognitive
benefit at Phase 2. No changes in CSF Aβ42. Failed to meet primary
and secondary endpoints at phase 3.
Discontinued [63]
β-Secretase
modulators
MK-8931 3 Reduced CSF Aβ compared to controls. Safe and tolerable at Phase 2. Recruiting for
Phase 3
[64]
CTS-21166 1 Dose dependent reduction in plasma Aβ. Completed [65]
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[72] meanwhile tests the effect of starting anti-Aβ treat-
ment at the pre-symptomatic stage, in individuals pre-
dicted to develop LOAD on the basis of brain amyloid
accumulation as measured by positron emission tomog-
raphy (PET) imaging. This will effectively test the hypoth-
esis that anti-Aβ treatments provide cognitive benefits
when given earlier in sporadic AD.
Another prominent suggested reason for clinical failures
of anti-Aβ drugs in particular are that the agents used ini-
tially were not properly validated and were flawed [68]. A
recent study has shown the monoclonal anti-Aβ anti-
bodies, solanezumab and crenezumab, fail to target hu-
man Aβ as effectively as they target over-expressed
human Aβ in mouse models [73]. The possibility was alsocountenanced that only amyloid plaques, potentially func-
tionally inert [74], rather than soluble Aβ oligomers were
targeted in early trials. Furthermore monotherapies may
not be capable of effectively reducing Aβ plaque load. A
double pronged approach to reduce Aβ by both active im-
munisation and inhibition of β-secretase has effectively
cleared plaques in mice [75]. However, as reviewed re-
cently [67], therapeutic approaches targeting plaque and
approaches targeting soluble Aβ have both now been
tested in humans, with equally negative outcomes.
Whilst the latter conclusions suggest that anti-Aβ
treatments may be failing because they poorly target Aβ
in human tissue, the conclusion does not disprove an al-
ternative view for the failure of clinical trials, namely
that Aβ is not responsible for all AD. Indeed for some
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[76] and the validation that bapineuzumab does effect-
ively bind Aβ in human tissue [73], but did not provide
recovery in clinical trials, only provides support for this
view. In the following sections we elaborate on the notion
the central focus on Aβ is, on the available evidence,
unwarranted.
Evidence Supporting the Amyloid Hypothesis is
Equivocal
The Aβ deposition paradox
“How wonderful that we have met with a paradox.
Now we have some hope of making progress.”– Niels Bohr
Aβ deposition occurs in cognitively normal individuals
Up to 40% of non-demented elderly can reach some
level of neuropathological criteria for AD [77]. A positive
correlation also exists between Aβ deposits and in-
creases in phosphorylated tau, the other major cerebral
histological inclusion in AD protein, in cognitively nor-
mal patients [78]. In one study only 17% of cognitively
normal elderly patients had few or no degenerative brain
changes [79], and in neuroimaging amyloid-PET studies
10-30% of cognitively normal individuals have amyloid-
positive scans [80]. Around 50% of people over the age
of 85 have AD [81], rising to 77.5% of centenarians who
meet criteria for mild confusion or severe dementia
based on cognitive testing [82]. This could be inter-
preted to suggest that amyloid deposition is predomin-
antly associated with normal aging and is not a disease
per se.
Not only does this paradox create difficulty for diag-
nosing disease by Aβ plaque deposition, it remains awk-
ward for the amyloid hypothesis. It is suggested that
individuals with high plaque burden, but are cognitively
normal, are in a pre-clinical AD stage [83], since the
progression of mild-cognitive impairment to AD is as-
sociated with the Aβ deposits [84]. However recent
in vivo imaging techniques illustrate that some non-
demented patients can have plaque burdens equivalent
to those seen in demented patients [85], and amyloid
deposition commonly plateaus, despite declining cogni-
tion [86]. In contrast, other markers of advancing AD
pathogenesis such as synaptic loss, NFTs, and microglial
activation correlate with the course of disease [87].
Conversely, neurodegeneration can appear independ-
ently of plaque deposition [88]. Notably too, individuals
with Trisomy 21 (Down’s syndrome), who have a triple
copy of APP universally have elevated Aβ and diffuse
non-fibrillar plaques that begin developing as early as 8years of age, yet they do not necessarily develop demen-
tia by their 70s [13]. Thus, the link between Aβ deposits
and causality remains uncertain.
In sum, the distribution of amyloid deposits in the brain
does not correlate well with neuropathology, loss of neural
function from specific brain areas, or cognitive impair-
ment. A conclusion that plaque is not the cause of LOAD
provides one possible explanation for Aβ vaccination trials
not improving patient outcome, even when plaque was
removed.
Why are plaques present in cognitively normal individuals?
Several valid interpretations of AD data could equally
explain the Aβ deposition paradox:
1. The type of plaque is important for cognitive
decline. Plaques can be either diffuse, fibrillar or
dense cored, and fibrillar amyloid plaques may
represent the toxic plaque in the AD brain [89].
Some suggest a rise in fibrillar plaque load is
correlated to dementia [90], but both diffuse and
fibrillar plaques exist in cognitively normal people
[91] and in any event plaques are questioned as a
cause of cognitive deficits [92].
2. Plaques may be non-toxic, but could become toxic
when bound to metal ions [93].
3. Some individuals may have a ‘cognitive reserve’, a
hypothetical concept described as accumulating
over a lifespan, allowing them to cope with more
amyloid [94].
4. Amyloid fibrils may be biologically inert [74] casting
doubt over the role of these lesions in the AD brain.
5. Amyloid plaques are not the cause of AD, rather it is
soluble Aβ oligomers, a theory with limitations
(discussed in detail below).
6. Another possibility, difficult to resolve, is that
Aβ plaque load contributes in only some cases of
AD, together with the simply corollary that it
has little to do with outcome in many cases of
the diseases.
7. Plaques could be an occasional by-product of APP
cleavage with variable, if any, mechanistic
consequence.
8. Plaques may be formed for a purpose, as a
cerebral blood vessel sealant to maintain vascular
supply to the brain during aging [95]. The
implications of reduced clearance of brain Aβ
and the presence of amyloid plaques in the
cerebral vasculature are reviewed in depth
elsewhere [96].
Causal or not, why do Aβ plaques accumulate? Studies
of EOAD mutations suggest they arise from increased
cleavage of longer, more amyloidogenic forms of Aβ.
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cases lacking EOAD mutations, and in non-demented
individuals. Failed clearance of Aβ via reduced levels of
Aβ cleaving enzymes such as neprilysin [97] and insulin-
degrading enzyme [98] may allow plaque to accumulate.
Also, the risk allele APOE4 may relate to reduced Aβ
clearance from the brain [99]. Whilst used as evidence
for the amyloid hypothesis, these latter explanations for
plaque accumulation also fit with the other plausible ex-
planations for plaque accumulation outlined above.
The rise of the soluble Aβ hypothesis
Rather than considering that the unreliability of plaque
as a disease marker may reflect badly on the amyloid hy-
pothesis, its guardians embraced soluble Aβ oligomers
as a cause of AD [100]. Yet, as we elaborate in the next
section, concerns have been voiced about the oligomer
hypothesis. These include a suggestion the amyloid hy-
pothesis is “…that invisible molecules target invisible
structures” [101], with new information interpreted within
a constantly fluctuating amyloid hypothesis, rather than
being molded into alternative hypothesis which may
better explain disease causality. Regardless, the amyloid
hypothesis has shifted in recent years to suggest soluble
Aβ oligomers, rather than plaques, are responsible for
neurodegeneration.
Uncertainty surrounding the presence of Aβ oligomers
in vivo
Oligomers are seen in the brain tissue of AD mouse
models, although this does not correlate with cognitive
decline [102]. Nevertheless, in one study oligomers were
found in post-mortem human AD brains but not cogni-
tively normal controls [40]. Furthermore, oligomers ap-
peared to differentiate AD, dementia without AD pathology
and cognitively normal patients in another [103]. This evi-
dence is much cited in support of a role for oligomers in
AD, but the data fail to define clearly which manifestation
of many possible Aβ oligomers are toxic, or if Aβ oligomers
are responsible for toxicity [104].
Debate also continues over the nature of amyloid assem-
blies in vivo, with studies reporting various assemblies
showing different toxic effects (reviewed in [105]). More-
over, at present it is only possible to study Aβ oligomers
secreted from in vitro cultures, or extracted from post-
mortem brain tissue [105,106]. Accordingly, some have in-
ferred current evidence for Aβ oligomerisation may simply
be an artifactual consequence of detection techniques
such as sodium dodecyl sulphate (SDS) polyacrylamide gel
electrophoresis (PAGE) [107]. Hence it is not yet clear if
Aβ oligomers are present in the original tissue, or rather
arise due to experimental manipulations.
For example, SDS-PAGE can detect Aβ oligomers in
human brain homogenates, yet surface-enhanced laserdesorption/ionization time-of-flight MS (SELDI-TOF MS),
which requires less manipulation of samples prior to
analysis, fails to detect dimeric Aβ in human brain ho-
mogenates [107]. Both SDS-PAGE and SELDI-TOF MS
could detect Aβ monomers from human brain hom-
ogenate. As the authors note, this suggest an over-
reliance on low-resolution techniques, such as immuno-
blotting, may have distorted our understanding of Aβ
biochemistry in the in vivo human brain. Clearly, our
understanding of the true biochemistry and presence of
Aβ monomers, dimers and higher order oligomers in
the human brain in vivo is limited. Unfortunately, data
that brought the amyloid hypothesis to its current, Aβ
oligomer-based state, including the aspects concerning
synaptotoxicity, arose from material driven by such
low-resolution techniques.
Studying Aβ oligomer toxicity in vivo is methodologically
difficult
As we have discussed above, support for a role of
Aβ-oligomers in AD derives from experiments showing
that injection of oligomers into the brain causes deficits
in synaptic plasticity, learning and memory, and reduces
synaptic spine density. However, there are several meth-
odological aspects of these experiments which give cause
for concern:
1. Some studies involve injection of synthetically
derived peptides into the rodent brain, that were
first crystallised into oligomers in vitro. These
synthetically-derived peptides lack post-translation
modifications, and may be different from Aβ peptides
produced in the human brain [108].
2. In humans Aβ oligomers associate with lipoproteins,
which may prevent Aβ-related toxicity, whereas
synthetically derived Aβ are applied without these
lipoproteins [109]. Clearly, this questions their
physiological relevance.
3. Oligomerisation of Aβ may be stimulated by its
adherence to the implanted plastic pumps used to
deliver peptides [41].
4. The physiological relevance of injecting a bolus dose
of either synthetically or human derived Aβ-oligomers
into an intact rodent brain is doubtful, since this
experimental protocol scarcely mimics the
deposition of Aβ in vivo [110].
Clearly, models for testing Aβ oligomer toxicity in vivo
must be considered in the context of our limited under-
standing of Aβ oligomer biology in vivo and in the con-
text of technical limitations summarised above. Data
from these studies cannot yet be confidently interpreted
to elucidate the pathogenic mechanisms occurring in the
human brain.
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In sum, the doubts associated with Aβ plaques have
driven the field towards considering oligomers as the
central toxic species. However, a new set of problems
arise from a lack of unequivocal evidence that Aβ olig-
omers are toxic in vivo [104]. There is yet to be a study
convincingly establishing a relationship between spe-
cific conformations of oligomers and the initiation of
disease in vivo, clearly in part due to methodological
difficulties. Conflicting data from separate groups must
be reconciled to gain a true understanding of Aβ biol-
ogy in the normal and diseased brain. Standardising
experimental protocols for identifying Aβ species is an
important first step [111]. At this stage, a harsh inter-
pretation is that perceived Aβ toxicity may represent
experimental artefact rather than the true function of
Aβ in vivo during the disease process. More likely, the
role of Aβ, in whatever forms it is active, will surely ul-
timately need to fit into a broadened holistic view of
disease.
Key Observations in Human AD are Poorly
Understood and Poorly Modelled
AD symptoms and pathology are heterogeneous
The similarities between EOAD and LOAD pathology
are integral to the amyloid hypothesis. Yet, both LOAD
and familial EOAD are highly heterogeneous. They exhibit
(1) different ages of onset [112], (2) differing temporal
progressions [113], (3) different and varying cognitive
symptoms [114] and (4) dissimilar pathological presen-
tations [115].
Furthermore, a third of patients with EOAD show
non-memory symptoms, whilst in LOAD only 6% have
non-memory symptoms [116]. In twins environmental
influences play a part in the timing of onset and on the
levels of pathological markers at the end stage [117].
This heterogeneity has been recognised in recent AD
diagnostic guidelines from the National Institute on
Aging (NIA) and Alzheimer’s Association (AA) [118].
Important to note also is that although essentially
100% of individuals with Down’s syndrome have neuritic
fibrillar plaques and NFTs by the fifth decade, the onset
of dementia is highly variable, with only 70% becoming
demented by their 70s, but with most maintaining their
baseline cognitive abilities through their 40s and into
older ages [13].
AD brains show mixed pathological presentations
Regional aggregation of Aβ may differ in familial and
sporadic cases. Remarkably, amyloid deposition is ac-
tually greater in some regions in sporadic AD cases
than in early onset cases with presenilin mutations
[119], indicating not all cases of AD follow the samedistinct pattern of amyloid deposition as suggested in
2002 [120]. This observation alone raises doubt that
the clinical phenotype of AD is solely related to Aβ
deposition.
Furthermore, up to 50% of AD cases have mixed patholo-
gies with other neurodegenerative conditions. For instance,
α-synuclein deposition (otherwise seen in Lewy bodies), is a
common co-morbidity with amyloid deposition, with more
than 50% of AD patients also exhibiting α-synuclein accu-
mulation [121].
Many consider disease heterogeneity as the manifestation
of human genetic variation and environmental factors
influencing progression of an Aβ or a tau-driven dis-
ease. Animal models provide support for this view, since
they show homogeneous disease phenotypes, where
variation can be introduced through environmental ac-
tions such as exercise and environmental enrichment
and through mouse strain genetic background, provid-
ing a model for the amyloid hypothesis. However, as we
shall next discuss, animal models may not truly reflect
either LOAD, or even all cases of EOAD. A real possi-
bility, instead, is that human AD may be heterogeneous
in presentation because the causes of AD may be hetero-
geneous, causing the diversity of symptoms that character-
ise the disease.Pre-clinical AD models are not representative of human
disease
Almost all mouse models of AD are engineered to
over-express human APP to such an extreme extent that
animals show pathology within months of birth. The treat-
ments in current human testing have usually been shown
to alter this pathology before being developed for the
clinic. However, this approach has yet to produce a re-
sult that has translated to a positive human clinical
outcome [66].
Little evidence indicates that APP is overexpressed in
the human AD brain [122]. Indeed, total Aβ may be re-
duced [123]. More worrying, most mouse models do not
show substantial neuronal loss, despite the presence of
large depositions of amyloid [124]. Further, in contrast
to human AD, where synapse loss is integral, mice show
a highly variable presentation. Some mice show increased
synaptic density in specific brain regions, while most
models show reduced synaptic density.
Thus, while providing reasonable models for assessing
the ability of a treatment to remove Aβ in vivo, and for
investigating the relationship of Aβ to other features
of the disease, such as its inflammatory components
[125], the reality is that removing an overexpressed Aβ
molecule in these mice may not be relevant to remov-
ing an under expressed, but aggregated molecule, from
the human brain. Additionally, a number of questions
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human AD:
1. Overexpression of wild-type APP, rather than mutant
human APP, can cause memory impairments in mice
independently of amyloid deposition [126,127]. APP
overexpression may therefore only model rare forms
of AD in which APP locus duplication is linked to
EOAD [128]. Such duplication is associated with a
very limited number of early-onset cases [129,130].
This questions the validity of mice overexpressing
mutant APP. Further, it raises concerns about controls
used in most mouse experiments; i.e. studies of
age-related cognitive decline should use mice
expressing wild-type APP at comparable levels to
over-expressed mutant-APP, alongside the commonly
used non-transgenic wild-types as controls, but
usually do not [131].
2. Despite increases in amyloid, a number of mouse
studies failed to detect any cognitive abnormalities
[132]. For example, mouse models expressing
familial AD-related mutant APP revealed no
cognitive deficits [133]. Remarkably, in one report,
overexpression of mutant human protein actually
improved the cognitive performance relative to
controls [134].
3. Mouse models of AD deposit peptides that are
distinct from those found in the human brain, an
important consideration in the design of drugs
targeting Aβ removal [135,136].
4. The phenotype of AD mouse models varies
depending on the background strain used, and can
affect the outcome of drug studies [137]. Prudence
therefore requires drugs to be investigated in
multiple mouse lines and models, but this is not
often done.
5. A related concern is that cognitive testing of mice
requires updating [138].
6. While expressing the human APP gene, genetic
animal models of AD also express endogenous,
non-human APP. A critical question remains as to
the role of endogenous mouse amyloid and APP in
these models. Evidence suggests that the
endogenous protein has an essential role in learning
but this has barely been studied [139]. If true then
removing endogenous Aβ in these mice, and indeed
in humans, may have detrimental effects on
memory, thereby contributing to the very problem
they are designed to treat.
7. Both EOAD and LOAD are pathologically
heterogeneous and many non-genetic risk factors
for disease also exist, for instance Type II diabetes.
Mouse models poorly represent these features of
human AD.Development of novel pre-clinic models to improve
translation of drugs to the clinic
Given the limitations of the mouse models, several groups
have attempted to investigate alternatives. This includes
other species that may better recapitulate AD pathology
including rats, octodon degu, chicks, dogs, guinea pigs,
rabbits, dolphins and non-human primates, although
these are much more expensive to investigate and some
still rely on APP over-expression.
Notable exceptions to the over-expressing mouse models
include the senescence accelerated mouse model (SAMP8)
[140] and the anti-NGF mouse [141]. These latter models
replicate several features of AD without relying on human
familial mutations. Others have used mice with inducible
neuronal loss to replicate the patterns of loss seen in hu-
man AD [142]. Stimulation of inflammation also recapitu-
lates many AD features in mice, including increased levels
of cleaved APP fragments, altered tau phosphorylation
[143] and declining motor and cognitive skills.
Recently a more relevant mouse model was created in
which humanized Aβ, with human AD-causing mutations,
was inserted into endogenous mouse APP [144]. These
mice showed Aβ pathology, neuroinflammation and mem-
ory impairment, although there was an absence of tau
pathology. This study supports a role for mutant APP
(but not necessarily for Aβ per se) in some familial forms
of disease. It does not however show Aβ causality in more
common sporadic forms of disease. It is also prudent to
recall that the majority of familial cases of AD are linked
to mutations in presenilin genes, rather than mutations in
APP, which are rare [145].
We are intrigued by the highly relevant modelling of
AD based on other risk factors of disease. For example,
diabetic mice develop many similar features to AD mice
[146] and a mouse model of chronic heart failure shows
alterations in the metabolism of cerebral Aβ and cogni-
tive impairments [147]. These mouse models show it is
not necessary to have familial AD mutations, nor do
they need to have the aggregating form of amyloid, to
re-create several features of disease. However in general,
at this stage, the genetic mouse models hold front and
center stage in AD studies. Studies based on these need
to be increasingly treated with caution and consideration
given to the use of different models.
Genetics Paint a Complex Picture of AD
Pathogenesis Beyond Aβ
A complex picture indeed
It is widely accepted that Aβ, when injected or over-
expressed in substantial excess, can cause pathology in ro-
dents, but what is the scenario by which genetic mutations
in the human cause AD? APP trafficking, function and
cleavage is complex and highly controlled. We show in
this section that mutations in APP can cause changes to a
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synaptic function. Meanwhile, presenilin mutations impact
the cleavage of numerous proteins also with synaptic func-
tions. Thus, even in EOAD caused by mutations in APP
or presenilin, Aβ may not be the sole basis of disease. In
sum, a valid, but inconvenient interpretation of AD genet-
ics is that the aberrant processing of APP, or of other pro-
teins cleaved by presenilin containing enzymes, is the key
contributing factor in familial AD, rather than solely aber-
rant production of Aβ that contributes to histopathology.
Furthermore, as we first discuss below, given the numer-
ous genes and processes implicated in AD, it seems highly
unlikely that any single gene such as APP alone will ac-
count for this disease in the majority of AD cases.
The genetic risk factors for AD are many and varied
Genome-wide association studies (GWAS) have identified
a number of genetic risk factors for AD. To date, the most
emphatic demonstration that numerous genes contribute
to the risk of AD has come from a meta-analysis of four
GWAS data sets consisting of 17,008 AD cases and
37,154 controls from 15 countries [148], which implicated
11 new regions of the genome as risk factors for AD. The
findings reinforce the importance of the innate immune
response and inflammation (HLA-DRB5/DRB1, INPP5D,
MEF2C) already implied by previous work (CR1, TREM2).
Also reinforced is the importance of cell migration
(PTK2B), lipid transport and endocytosis (SORL1). New
hypotheses on AD pathogenesis have also emerged related
to genetic mutations in molecules associated with hippo-
campal synapse function (MEF2C, PTK2B), the cytoskel-
eton and axonal transport (CELF1, NME8, CASS4) as well
as myeloid and microglial cell functions (INPP5D). While
efforts are often made to relate new data to the amyl-
oid hypothesis [149], many of these mutations are not
conveniently placed within it.
Furthermore, new research showing the molecular sig-
natures of AD vs. normal aging indicates that the molecu-
lar phenotype of AD is highly complex, with a variety of
transcriptional changes differentiating AD from aging.
Transcriptional profiles for neuroinflammatory and lipid
metabolism genes in particular are altered early in disease
in this dataset [150].
GWAS and ageing data is therefore increasingly con-
sistent with a view that Aβ (or more likely altered APP
production, function and cleavage) exists somewhere
within a highly complex disease framework that is yet to
be understood. It is unclear whether numerous mecha-
nisms converge on a single primary pathway, or, if AD will
need to be redefined as a host of diseases manifesting ul-
timately as memory loss, resulting from synapse loss and
neurodegeneration. The latter view, that memory becomes
problematic when brain function is disrupted, has simple
appeal, but is a nightmare from a therapeutic perspective.Mutations in presenilin genes do not always increase Aβ
cleavage
There is a widespread assumption that all the genetic
links to AD effectively modify the cleavage of Aβ to pro-
duce more of the longer forms, Aβ42 and Aβ43, or in-
crease the ratio of longer Aβ peptides compared to shorter
ones and in turn that this is causative of AD. Certainly, evi-
dence for increased levels of Aβ42, or for increases in the
Aβ42:Aβ40 ratio as a result of APP, PSEN1 and PSEN2
mutations has been found in both in vivo and in vitro stud-
ies [151-153]. However the conclusion is not warranted in
view of the full data set.
In a study examining the effects of eight FAD PSEN1
mutations on Aβ production, most of the mutants pro-
duce no change in the Aβ42:40 ratio [154]. Furthermore,
family members with the same FAD mutations exhibit
heterogeneity in their clinical and neuropathological
phenotypes [155]. These results are supported by studies
showing heterogeneous effects of FAD PSEN mutations
on the Aβ42:40 ratio depending on the mutation [156-158],
but are contradicted by reports of universal increases in
Aβ42 as a result of FAD mutations [153,159]. Nevertheless
as it stands, it seems unlikely that FAD mutations lead
to the same phenotypic amyloid cleavage, resulting in
increased Aβ42 and/or increases in the Aβ42:40 ratio.
Newer evidence for the role of a longer form of Aβ,
Aβ43, in disease pathogenesis may be the result of a fa-
milial AD-linked presenilin mutation [160]. The Aβ43:
Aβ42 ratio is increased in mice harbouring this particu-
lar presenilin mutation, with no change in Aβ40 or Aβ42
levels [160]. We simply cannot draw conclusions at this
stage about the role of any form of Aβ in disease. It
would be prudent to include measurements of a variety
of Aβ cleavage forms in disease, and determine the im-
portance of qualitative versus quantitative changes in Aβ
production over time, during disease [161].Presenilin has important physiological functions
independent of Aβ cleavage
Evidence from rare clinical case studies illustrates muta-
tions in presenilin genes can be associated with neurode-
generation independently of amyloid plaque deposition.
Presenilin mutations have been found in frontotemporal
lobe dementia (FTD) without amyloid pathology [162],
dementia with Lewy bodies [163], posterior cortical atro-
phy dementia [164] and atypical dementia [165]. However
newer evidence suggests presenilin mutations may not be
the true causes of all these amyloid-independent neurode-
generative states, as genetic defects in the progranulin
(PGRN) gene can explain FTD, atypical phenotypes and
parkinsonism, also associated with presenilin mutations
[166,167]. There is however at least one clinical case in-
volving a point mutation in PSEN1, that is associated with
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without amyloid plaques [168].
Regardless, in AD, where amyloid plaques are present,
there is good reason to suggest that the effects of prese-
nilin mutations on APP biology may account only in
part, if at all, for the AD pathology they associate with.
In fact, there are several known functions for presenilin
which could be impacted by FAD-linked presenilin mu-
tations. These alternative functions include roles in
macroautophagy, APP vesicle transport, cell survival,
cleavage of a wide variety of possible substrates, and the
importance of presenilin for synaptic function, which to-
gether have culminated in the presenilin hypothesis of
AD [169]. There are also links between presenilin func-
tion and the innate immune system, which may account
for the presence of neuroinflammation in EOAD, inde-
pendently of amyloid [170]. The numerous effects FAD-
linked presenilin mutations would have on all these pro-
cesses could together account for AD independently of,
or additional to, any effect on amyloid pathology.
The Presenilin hypothesis of AD
A ‘presenilin hypothesis’ of AD has been articulated
[169]. We further suggest that presenilin mutations fit
best within a hypothesis that AD is a disease driven by
synapse loss. Though the AD literature has largely fo-
cused on the role of PSEN1 in APP cleavage (Figure 2),
presenilin mutations affect a range of proteins and
therefore processes, particularly those involved in syn-
aptic function, as summarised above. Given that prese-
nilin appears important for cleaving proteins that are
crucial at synapses, presenilin mutations would lead to
synaptic dysfunction. It would also follow that drugs
targeting presenilin in humans are destined to have
profound detrimental effects on the brain with long-
term use. This indeed was the result of recent clinical
trials of presenilin antagonists, also termed γ-secretase
inhibitors (Table 1).
Nevertheless γ-secretase inhibition continues to be pur-
sued. Recent evidence using conditional presenilin KOs
has suggested that presenilin function is not as critical in
the adult brain as the developing brain, allowing the field
to justify its ongoing use as a target for drug intervention
(See [171] for a detailed review). This is in spite of the res-
ervations that emerge from consideration of data reviewed
above.
APOE4 dysfunction is related to inflammation
The APOE4 allele has been a known genetic risk factor
for sporadic AD, and it remains the strongest known
[22]. It has been linked to the amyloid hypothesis by indi-
cations it is involved in the clearance pathway of Aβ, with
deficits causing a toxic Aβ accumulation and aggregation
[172]. Meanwhile, an alternative avenue of enquiry showsthat APOE4 has intimate connections with innate im-
munity, and this was reasoned to explain its broader re-
lationship with inflammatory disease, not just AD. One
observation is that APOE suppresses TNF secretion
from inflammatory cells [173] (also see [174]). Import-
antly an APOE mimetic that suppresses TNF secretion
has successfully treated experimental models of neurode-
generative disease, including traumatic brain injury [175],
stroke [176] and AD [177]. As well as reducing behavioral
deficits, in the study of AD, the APOE mimetic also re-
duced Aβ plaques and tau tangles [177]. The relationship
of APOE4 to inflammation therefore opens a channel of
enquiry directed to explain why stimulation of APOE
expression in mice enhances normal Aβ clearance (both
soluble oligomers and plaques) and reverses behavioural
deficits. In line with the observation of the link between
presenilin mutations and inflammation, the links between
APOE4 and inflammation further point to inflammation
as a major player in AD pathogenesis independently
of Aβ.
Understanding the complexity of APP biology
independently of Aβ is important to understanding AD
pathogenesis
APP synthesis, trafficking and cleavage are complex and
highly regulated processes (Figure 2). It is important to
recognise that familial AD APP and presenilin mutations
may not only impact Aβ production, but also the produc-
tion of the other peptides produced from APP including
sAPPα, sAPPβ, p3 and AICD, as well as the relative levels
of full-length APP. Interestingly, overexpression of AICD
can cause an AD-like phenotype [178], whilst increased
cleavage of sAPPβ is associated with familial Danish De-
mentia with similar aetiology to AD [179]. Furthermore
lowered levels of neurotrophic sAPPα are seen in AD,
and mutations which inhibit the α-secretase enzyme
ADAM10, which liberates sAPPα from its precursor, are
found in the promoter region and coding sequence of
some individuals with AD [180]. Depletion of sAPPα by
inhibition of ADAM10 trafficking can bring about spor-
adic AD phenotypes [181], corroborating an independ-
ent role for APP cleavage products other than Aβ in
bringing about disease phenotypes.
Whilst the functions of p3 and sAPPβ are little ex-
plored (which in itself is a remarkable reflection of the
intense focus on Aβ at the expense of other cleavage
products of APP), a wealth of evidence exists for physio-
logical functions of sAPPα, Aβ, AICD and full-length
APP [182] (Figure 2). These studies raise questions as to
whether familial AD driven by presenilin and APP muta-
tions is primarily a result of aberrant Aβ expression, or
if it is in fact a result of altered APP cleavage, and the re-
sultant effects of altered APP cleavage on sAPPα, sAPPβ,
Aβ, AICD, p3 and full-length APP. This brief discussion
Figure 3 Controversies and Inconsistencies Within the Current
Amyloid Hypothesis. 1. Aβ deposition occurs in cognitively normal
individuals; 2. There is a weak correlation between plaque load and
cognition; 3. The biochemical nature and presence of Aβ oligomeric
assemblies in vivo is unclear; 4. Pre-clinical AD models based on
EOAD-linked mutations are biased toward the amyloid hypothesis;
5. Pathological heterogeneity and comorbidities are unexplained
by the amyloid hypothesis; 6. Aβ has a normal physiological role
and targeting Aβ may disrupt these roles over the long term; 7.
Genetic factors linked to AD can be interpreted independently of
amyloid; 8. APP cleavage and function is more complex than solely
the production of Aβ, indicating other APP family members may
play a role in disease progression; 9. The triggers of synapse loss,
neuronal loss and neuroinflammation in AD are still unclear; 10. The
relationship between Aβ and tau pathologies is unclear; 11. The
onset of dementia in Down’s Syndrome is highly variable, despite
the presence of fibrillar plaques in 100% of Down’s individuals by
the fifth decade; 12. The APOE4 genotype has numerous functional
effects, rather than solely relating to reduced Aβ clearance,
including links to enhanced inflammatory phenotypes. Each of
these points are discussed in detail in the text.
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tions of C83, C99 (Figure 2), the different functions of
the multiple isoforms of APP including APP695, APP751
and APP770, or the highly homologous proteins to APP,
APLP1 and APLP2, which are also physiologically
expressed in the human brain and may serve redundant
functions with APP proteins.
There are many unresolved issues in the amyloid
hypothesis
The field has pursued the idea that Aβ accumulation is
the central cause of AD based in part on an amyloid-
centric interpretation of the genetics. Yet as described
above, numerous products of APP are affected by APP
mutations and by presenilin mutations.
One valid conclusion, in view of the complex biology
of APP function and cleavage, is that APP and presenilin
mutations cause AD because they alter several cleavage
products of APP, which each in turn contribute to AD.
In this view of disease, alterations in Aβ expression
would only be a part player in pathology or, perhaps
even, a by-product, and an indicator of altered APP
function and cleavage. This conclusion, if true, would
predict that clinical trials of anti-Aβ drugs will fail even
in some or all cases of EOAD.
Meanwhile, analysis of the effects of presenilin muta-
tions does not lead to the conclusion that AD is caused
by Aβ. The cleavage of a range of proteins is affected by
presenilin mutations and many would affect the synapse.
In fact as we illustrated, presenilin mutations do not al-
ways alter Aβ production as may be expected. Finally,
many mutations and risk factors associated with AD may
not relate to Aβ metabolism.
Yet, amyloid-centric interpretations continue to flour-
ish. A recent study showed that a mutation, determined
to modestly decrease Aβ levels of the course of lifespan,
is preventative of AD [23]. This data was taken to sug-
gest that a life-long reduction in Aβ reduces the risk of
AD. However, the mutation also results in marginally
(albeit non-significant) increases in levels of beneficial
neurotrophic sAPPα. Regardless, an alternative interpret-
ation is that a life-long change in APP function and
cleavage could protect against AD independently of low-
ered Aβ production.
Future Directions
The emergence of more holistic approaches to
understanding AD pathogenesis
As suggested by Figure 3, the amyloid hypothesis is at
least incomplete, and quite possibly largely incorrect.
Therefore it follows that therapies targeting Aβ or APP
processing may not treat LOAD, and possibly may not
even work in some cases of EOAD. Given this conclu-
sion, it is worthwhile to consider alternative possibilities.There are a number of theories in the literature that
must be given serious consideration and ultimately inte-
grated into a holistic view of disease. We will elaborate
on just some of these, below.Insulin resistance and Inflammation
It is suggested that a similar pathogenesis operates in
AD as in Type 2 diabetes (T2D), but restricted to the
brain, thus describing AD primarily as a result of cere-
bral insulin resistance [183]. Certainly cerebral insulin
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the appropriate alterations in post-insulin receptor
intracellular signalling have been impressively demon-
strated in fresh AD autopsy brains [185]. This idea is
likely inseparable from the argument that AD is an in-
flammatory disease, since evidence that excessive TNF
induces insulin resistance is biochemically precise
[186] and, as has been reviewed [187], is widespread
across many inflammatory diseases, infectious and
sterile. Moreover an agent that inhibits TNF produc-
tion [188] and another that controls insulin resistance
[189] have both been shown to reverse AD in experi-
mental models [190].The inflammatory hypothesis of AD is a valid alternative
to the amyloid hypothesis
We and others have long proposed a role for neuroinflam-
mation, driven by microglia and astrocytes, as a trigger
for Alzheimer’s pathogenesis [46,125,187,191]. The case
for chronic inflammation, as classically defined, rather
than Aβ, being the primary initiator of AD has a long
history, with new evidence continuing to accumulate.
From 1989 it has been reported that inflammatory cyto-
kines are essential for the excess APP required for the
amyloid hypothesis of AD [192], as well as up-regulating
its cleavage to form Aβ [187]. In addition, parallel studies
demonstrating that oligomeric Aβ influences synapses
through inducing the inflammatory cytokine TNF
[187,193,194] have been enlightening. A possible role
for neuroinflammation in synapse pathology early in
disease has now been acknowledged [195] and there is
much evidence, from genetics and measuring indica-
tory of inflammation very early in AD, that it is in the
right place at the right time to be causal, and likely to
precede Aβ and tau pathologies [187]. More recently,
the clinically approved specific anti-TNF agent, etaner-
cept, is reported to prevent changes caused by admin-
istering Aβ to mice intracerebroventricularly [196].The tau hypothesis of AD
The concept of hyperphosphorylated tau being a pri-
mary mediator of AD, like amyloid, has a long history,
which continues to grow [197]. Much interest still exists
in where tau sits in the pathogenesis of AD [198]. In our
view, AD is sufficiently diverse that it is conceivable that
the role of tau, and where it sits in AD pathology, could
vary among individuals. If tau is a primary activator of
disease in some cases, it is imperative that the reported
harmlessness of phosphorylated tau to neurons during
mammalian hibernation [199] be discussed in AD re-
search circles. Furthermore, hyperphosphorylated tau
can be considered another histological sign of cytokine
activity [187].Redefining ‘neuroinflammation’ through viewing the
synapse as a complex multicellular structure is important
in future AD research
The inflammatory hypothesis is an example of how
amyloid and tau research can be integrated into a novel
set of ideas, both expanding the amyloid hypothesis and
including it. However, while we use the term ‘neuroin-
flammation’ throughout this text and elsewhere, we note
that neuroinflammation is poorly defined. In its simplest
form neuroinflammation is currently defined by altered
glial cell morphology and excess pro-inflammatory cyto-
kine release [46]. This must ultimately give way to a
more complex and subtle view of glial function/dysfunc-
tion within the multicellular synapse [200].
Stepping back to consider the multitude of factors we
have summarised above, a complex picture emerges that
consistently points to synaptic dysfunction and loss as a
major link between the diverse characteristics of the dis-
ease. We have recently pointed out the synapse needs to
be re-defined and understood as a multicellular structure
where glia play a critical role [46]. This allows us in turn
to re-imagine AD.
Microglia and astrocytes are essential to normal synapse
biology, including the removal [201,202] and formation of
synapses [203,204], and maintenance of synaptic function
[205,206]. Disruptions in signalling between glia and
synapses, which may involve several known cytokines
such as TNF, could therefore drive the well-known syn-
apse loss in AD, either independently of, or in conjunction
with Aβ [46].
A consequence of this interpretation is that the issue
may not be an upregulation of neuroinflammatory sig-
nalling from these cells per se, that is involved in disease.
Rather, expression of pro-inflammatory cytokines and
other neuronal and glial derived molecules regulating
the synapse could be disrupted subtly for a host of rea-
sons, well before frank inflammation is apparent. APP,
along with presenilin and indeed numerous other fac-
tors, may exert effects on the synapse through actions
on glial function, leading to either excess synapses
(as occurs in autism) or synapse loss (as occurs in AD).
This would modify glial function at synapses, and poten-
tially drive synapse loss. Thus, we propose that many of
the factors thought to cause inflammation are more
likely to cause a dysregulation of glial function at the
synapse in the first instance, long before changes in cell
morphology become obvious. Consequently, more subtle
mechanisms may underpin AD.
Clearly, understanding the physiological roles of micro-
glia and astrocytes at synapses, as opposed to simply con-
sidering them as cells with key roles in innate immunity
and ‘neuroinflammation’, is a critical avenue for future
research. We suggest future research will reveal that the
entire current concept of ‘neuroinflammation’ is poorly
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will require profound rethinking before we can truly
understand the role of glia in the unperturbed brain and
in AD pathogenesis [46].
Conclusion
In the words of Joseph Lister (1876)
"In investigating nature you will do well to bear ever
in mind that in every question there is the truth,
whatever our notions may be. This seems, perhaps, a
very simple consideration, yet it is strange how often it
seems to be disregarded. I remember at an early period
of my own life showing to a man of high reputation as a
teacher some matters which I happened to have
observed. And I was very much struck and grieved to
find that, while all the facts lay equally clear before
him, those only which squared with his previous theories
seemed to affect his organs of vision."
Lister’s quote is salient. Hypotheses are an important
part of any scientific method, but the sentiment of Karl
Popper, quoted earlier in this article, should be taken
seriously. Keeping Popper’s views in mind may prevent
us from becoming over-reliant upon, and blinkered by,
any single hypothesis for AD.
It has been said the amyloid hypothesis, like certain
banks, may have become too big to fail [101]. The hy-
pothesis may yet prove its merit, at least in some cases,
through early intervention trials with amyloid-directed
therapeutics [70,71]. However, on the basis of the data
discussed here, the role of Aβ as a primary cause of all
AD remains debatable. We are therefore concerned by
the suggestion that, if anti-Aβ treatments are success-
ful in patients with EOAD, this would support an argu-
ment for treating all AD with anti-Aβ drugs [207].
Such a conclusion would merit questioning without
direct clinical evidence that the treatments are effective
in LOAD.
We are not arguing that Aβ has no role. In fact it may
be a player in a more complex view of disease and, fur-
ther, its role may even be variable. We suggest instead
that to solve the complex riddle of AD, theoretical
models must expand beyond Aβ as the central cause of
dysfunction, instead including Aβ in a wider theory that
accounts for the extensive data and advances in neuroscience
that have accumulated over the last decade. Ultimately
it is critical that any role for Aβ must be placed in the
context of a holistic view of the disease that accounts
for all the data.
Even more so, with recent meta-analyses highlighting
some major pitfalls with experimental design and statis-
tical power in neuroscience [208,209], we need to be
wary. Conclusions drawn from any experiment must bereplicated before accepting them as fact, especially con-
sidering the difficulty in replicating in vivo studies when
using different background animal strains, and different
methodological approaches [210,211].
An important suggestion we make is that the concept
of neuroinflammation mediated by glia may need to give
way to a more subtle understanding of how aberrant
glial function at synapses drives AD. We suggest an al-
ternative view that, given evidence for synapse dysfunc-
tion as an early event in AD, synapse dysfunction may
ipso facto be the cause of AD. We recently suggested
[46] a new definition of the synapse as “…a complex, dy-
namic and often transient structure involving several cells
interacting within a sophisticated extracellular matrix and
milieu.” Within this framework, one of the normal roles of
glia in synapse structural plasticity is to modulate and
also remove synapses. Improving our understanding of
how dysregulation of the multicellular synapse leads to
aberrant synapse elimination will likely produce novel
insights into mechanisms of synaptic degeneration in
AD, and provide insights into the relationship between
synaptic degeneration and other pathological hallmarks
of the disease. The corollary of this is that if we can
identify signaling pathways that reverse glial mechanisms
leading to synapse removal, we may identify approaches
that could halt or even reverse AD, independent of spe-
cific cause. Regardless, if synapse loss is one of the earliest
events in disease then we must go back to first principles
and understand what drives this loss.
The primary point of our review is to suggest it is in-
appropriate to ignore equally valid interpretations of data.
There are many thousands of papers on Alzheimer’s
disease, and many of these papers can be interpreted in
alternative ways, while still more are contradictory to,
and/or inconsistent with, the amyloid hypothesis. There
are also many thousands more investigating mechanisms
driving synapse function and dysfunction that could be
linked to AD literature, given synapse dysfunction is a key
early event and accurate correlate of AD progression. We
conclude by suggesting the students, post-docs and young
faculty who will determine the course of AD research in
the next decade, must spend time reading this literature
extensively, and thinking deeply, and thus become the
next generation of leaders that, at the expense of time
away from the lab bench, determine the best pathway
forward.
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